市場調查報告書
商品編碼
1403487
到 2030 年器官保存解決方案市場預測:按解決方案、保存類型、器官、最終用戶和地區進行的全球分析Organ Preservation Solution Market Forecasts to 2030 - Global Analysis By Solution, Preservation Type, Organ, End User and by Geography |
根據 Stratistics MRC 的數據,2023 年全球器官保存解決方案市場規模為 2.7864 億美元,預計預測期內複合年成長率為 8.8%,到 2030 年將達到 5.0285 億美元。
器官保存溶液能夠在器官捐贈和移植之間的關鍵時期維持器官的活力,這使得器官保存溶液對於移植醫學至關重要。這些專門的解決方案提供了理想的保存環境,以保護器官免受缺血性損傷。這些解決方案有助於維持細胞完整性並防止細胞腫脹。
根據美國疾病管制與預防美國(CDC) 2020 年的估計,三分之一的糖尿病成人和五分之一的高血壓成人可能患有慢性腎臟病。根據 2021 年 CDC 報告,美國每年有 15% 的人患有慢性腎臟病。
由於導致器官衰竭的慢性疾病的增加,以及手術方法和免疫抑制藥物的改進,世界各地的器官移植率正在以不可阻擋的速度增加。此外,不斷成長的需求凸顯了器官保存解決方案對於移植手術的生存和成功至關重要,因此,我們正在努力增強和最佳化這些針對不同器官類型的解決方案,研究和開發正在進行中。
對於某些器官來說,儘管該領域取得了進展,但目前的器官保存方法可能會限制其存活,特別是在長期保存時。各種器官的複雜性及其不同的生理需求使得很難發展出普遍有效的解決方案。此外,需要繼續研究以全面了解每個器官的獨特儲存要求並提高當前配方的功效,以解決此限制。
只要冷凍保存技術不斷進步,器官保存市場就有望成長。冷凍保護劑和冷凍技術的進步可以延長器官保存時間並增加長期保存的可行性。此外,這將導致更靈活的器官移植安排和改進的後勤管理。
缺乏既定的器官保存協議給該行業帶來了障礙和風險。醫療機構和地區之間不同的協議可能會阻礙溝通並導致保留結果不一致。此外,建立廣泛認可的標準對於確保器官保存技術的可靠性和效率至關重要。
器官保存市場在多個方面受到了 COVID-19大流行的影響。器官移植手術受到影響,導致移植數量減少。這些因素包括醫療保健系統的中斷、後勤挑戰以及管理流行病的優先事項的轉變。器官移植因關閉、旅行限制和獲得醫療保健的機會有限而受到阻礙。此外,為了應對醫療保健預算和資源的財務壓力,器官保存的研究和發展也在改變。
威斯康辛大學解決方案 (UW) 部門預計將佔據最大的市場佔有率。腎臟、肝臟和胰臟器官移植經常使用 UW 溶液進行,UW 溶液是一種高效且適應性強的器官保存介質。由於其滲透壓、平衡的電解質成分以及減少細胞水腫的能力,建議將其作為器官獲取和移植之間關鍵時期器官保存的選擇。此外,該產品的廣泛接受度是由於成功的移植、悠久的臨床使用歷史以及保持器官活力的記錄。
器官保存市場在專科診所中以最高的複合年成長率成長。更專業的醫療保健服務趨勢以及對有針對性的、以患者為中心的護理日益成長的需求推動了專門從事器官移植和器官保存的專科診所的成長。移植前評估、器官保存技術和移植後護理只是這些診所提供的廣泛服務的一小部分。此外,隨著器官衰竭的日益普遍和移植技術的進步,患者正在尋求專業診所的專業知識,這些診所通常提供比傳統醫院更有效和個體化的護理。
北美在器官保存解決方案市場中佔有最大佔有率。這項優勢是由多種因素促成的,包括發達的醫療保健系統、高頻率的器官移植以及醫學和技術的進步。此外,該地區憑藉強大的法規環境、廣泛的研發支出以及積極採用尖端醫療保健解決方案,處於行業前沿。
亞太地區在器官保存解決方案市場的複合年成長率最高。許多因素正在推動該地區的快速成長,包括器官衰竭盛行率的增加、社會對器官移植的認知以及醫療基礎設施的進步。此外,亞太地區市場佔有率的成長不僅得益於器官保存技術的進步,還得益於對醫療旅遊的日益關注。
According to Stratistics MRC, the Global Organ Preservation Solution Market is accounted for $278.64 million in 2023 and is expected to reach $502.85 million by 2030 growing at a CAGR of 8.8% during the forecast period. Organ Preservation Solution has the ability to preserve organ viability during the crucial time between donation and transplantation, organ preservation solutions are essential to transplant medicine. The ideal preservation environment is provided by these specialized solutions, which are made to shield organs from ischemia damage. These solutions aid in preserving cellular integrity and preventing cellular swelling.
According to the estimates by the Centers for Disease Control and Prevention (CDC) in 2020, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. Per the CDC report issued in 2021, ~15% of people in the US suffer from chronic renal disease each year.
The world's organ transplantation rate is increasing at an unstoppable rate due to an increase in chronic diseases that cause organ failure as well as improvements in surgical methods and immunosuppressive medications. Additionally, the growing demand highlights how vital organ preservation solutions are to the survival and success of transplant operations, which in turn drives ongoing research and development endeavors to enhance and optimize these solutions for a variety of organ kinds.
The viability of some organs may be limited by some current organ preservation methods, even with advancements in the field, especially when done for prolonged periods of time. Developing universally effective solutions is challenging due to the complexity of various organs and their distinct physiological requirements. Furthermore, a comprehensive grasp of the preservation requirements unique to each organ and continuous research to improve the effectiveness of current formulations are necessary to address this constraint.
The organ preservation market is expected to grow as long as cryopreservation technology continues to progress. The prolongation of organ preservation periods and the enhancement of long-term storage feasibility can be possible through advancements in cryoprotectants and freezing techniques. Moreover, this can lead to more flexible organ transplant scheduling and improved logistical management.
The lack of established procedures for organ preservation creates obstacles and risks for the industry. Disparate protocols among healthcare facilities and geographical areas could impede communication and lead to inconsistent preservation results. Additionally, the establishment of widely recognized standards is essential to guaranteeing the dependability and efficiency of organ preservation techniques.
The market for organ preservation has seen a variety of effects from the COVID-19 pandemic. Organ transplantation procedures have been impacted, which has resulted in a decrease in transplant volumes. These factors include disruptions in healthcare systems, logistical difficulties, and a shift in priorities towards managing the pandemic. Organ transplantation has been hampered by lockdowns, travel restrictions, and limited access to healthcare. Furthermore, research and development for organ preservation solutions have also seen changes in response to the financial strain on healthcare budgets and resources.
It is projected that the University of Wisconsin Solution (UW) segment will command the largest market share. Organ transplants for the kidney, liver, and pancreas are frequently performed using the UW solution, an extremely effective and adaptable organ preservation medium. Because of its osmotic pressure, balanced electrolyte composition, and capacity to reduce cellular edema, it is the recommended option for organ preservation during the crucial time between organ procurement and transplantation. Moreover, its broad acceptance can be attributed to its successful transplantation outcomes, long history of clinical use, and track record of preserving organ viability.
The market for organ preservation is growing at the highest CAGR in specialty clinics. The growth of specialty clinics devoted to organ transplantation and preservation is facilitated by the trend toward more specialized healthcare services as well as the rising need for targeted, patient-centered care. Pre-transplant evaluations, organ preservation techniques, and post-transplant care are just a few of the extensive services provided by these clinics. Additionally, patients are seeking the expertise of specialized clinics, which often offer more efficient and personalized care than traditional hospitals, due to the increasing prevalence of organ failure conditions and advancements in transplantation techniques.
In the market for organ preservation solutions, North America holds the largest share. Numerous factors contribute to this dominance, such as a well-developed healthcare system, a high frequency of organ transplant procedures, and ongoing advancements in medical science and technology. Furthermore, the region is at the forefront of the industry because of its strong regulatory environment, large R&D expenditure, and proactive adoption of cutting-edge healthcare solutions.
In the market for organ preservation solutions, the Asia-Pacific region has the highest CAGR. A number of factors, including an increase in the prevalence of organ failure conditions, public awareness of organ transplantation, and advancements in healthcare infrastructure, are driving this region's rapid growth. Furthermore, the growing market share in the Asia-Pacific region can be attributed to the growing emphasis on medical tourism as well as advancements in organ preservation techniques.
Some of the key players in Organ Preservation Solution market include Paragonix Technologies, Inc, Organox Limited, Transmedics, Inc., Bridge to Life Ltd, Transplant Biomedicals, Accord Healthcare Inc., Waters Medical Systems LLC, Preservation Solutions, Inc. and Xvivo Perfusion AB.
In August 2023, US-based commercial medical group TransMedics Group announced the completion of the full acquisition of Summit Aviation, a premier US charter flight operator. The acquisition establishes TransMedics Aviation as the first integrated national provider of air logistics dedicated exclusively to organ transplantation in the US.
In July 2023, Organox Ltd. raised £25 million in a funding round that will allow the company to expand its operations in the U.S. on the back of significantly increasing demand from transplant centers, Oern Stuge, executive chairman, at Organox told BioWorld. The Oxford, U.K.-based company which makes systems to preserve and transport livers for transplant is also preparing for its eventual listing on Nasdaq, he added.
In March 2023, Paragonix Technologies, Inc., a leading organ transplant company, today announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners. This growth investment will bolster Paragonix Technologies' commercial footprint, including its ongoing extension of clinical service offerings and inventory expansion, and will enable the Company to further advance transplant innovations.